China National Pharmaceutical Modern announced that its wholly-owned subsidiary, China National Pharmaceutical Group Wichita Pharmaceutical Co., Ltd., has received a notice of compliance inspection for drug GMP. The relevant production lines of China National Pharmaceutical Wichita's Workshop 108 and the comprehensive raw material pharmaceutical workshop have passed the GMP compliance inspection. This GMP compliance inspection covers raw materials and is the first GMP compliance inspection for the product before it is launched. The workshops and production lines mentioned are all renovated old factory buildings, with a total construction investment of approximately 22.7604 million yuan. The products currently produced by the above production lines are Acarbose, with a designed capacity of 12 tons/year